Obermatt
See Similar Stocks →

Taysha Gene Therapies

NSQ:TSHA · US8776191061
BiotechnologySmall

360

21
Profit price74
Cash yield1
Price/Sales20
EV / Gross Profit1
Price/Book9
Return on Capital14
Cash Return on Capital32
Return on Equity16
Profit margins42
Accruals51
Owner Earnings Margin4
Sales growth32
Profit Growth38
Long-Term EPS Growth100
Reinvestment77
Price momentum65
Debt load21
Refinancing65
Debt Payback1
Liquidity12
Analyst ratings57
Opinion Changes19
Price Target Upside84
Market mood79
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Taysha Gene Therapies doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2019
Employees107
Websitetayshagtx.com
ISINUS8776191061
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyGeneticsCentral Nervous SystemNeuroscienceGenetic DisorderBiotechnologyLife Science

Description

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company’s lead clinical program, TSHA-102, i…

Analysis

Story stock

Taysha Gene Therapies, Inc. trades at an expensive price on a weak set of business metrics, a combination we flag as a story stock.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
47
2026

All-time high

47

Jun 2026

All-time low

42

Mar 2026

Average rank

45

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
20
—
—
—
Price/Earnings
78
—
—
—
Price/Book
9
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
55
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Taysha Gene Therapies with its peers
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Regenxbio
NSQ:RGNX
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Anavex Life Sciences
NSQ:AVXL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protara Therapeutics
NMQ:TARA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →